[1]World Health Organization. Global tuberculosis report 2013. WHO/HTM/TB/2013.11.Geneva: World Health Organization,2013.[2]Ginsberg AM. Tuberculosis drug development: progress, challenges, and the road ahead. Tuberculosis (Edinb), 2010, 90(3):162-167.[3]World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva: World Health Organization,2009.[4]刘宇红,姜广路,赵立平,等. 第四次全国结核病流行病学抽样调查——结核分枝杆菌耐药性分析与评价. 中华结核和呼吸杂志, 2002,25(4):224-227.[5]全国第五次结核病流行病学抽样调查技术指导组,全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8): 485-508.[6]Ahmad S, Jaber AA, Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis (Edinb), 2007,87(2):123-129.[7]Jadaun GP, Das R, Upadhyay P, et al. Role of embCAB gene mutations in ethambutol resistance in Mycobacterium tuberculosis isolates from India. Int J Antimicrob Agents, 2009, 33(5):483-486.[8]Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med, 2011, 155(8): 529-536.[9]Devillé WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol, 2002,2:9.[10]Zamora J, Abraira V, Muriel A, et al. Meta-Disc: a software for meta-analysis of test accuracy data. BMC Med Res Me-thodol, 2006,6:31.[11]Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg, 2005, 79 (1):16-20.[12]俞慧强, 郑辉烈, 李悦, 等. Meta 分析发表偏倚诊断方法研究. 中国卫生统计, 2011, 28(4): 402-405.[13]Escalante P, Ramaswamy S, Sanabria H, et al. Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. Tuber Lung Dis,1998,79(2):111-118.[14]Ramaswamy SV, Amin AG, Goksel S, et al. Molecular gene-tic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2000, 44(2): 326-336.[15]Lee AS, Othman SN, Ho YM, et al. Novel mutations within the embB gene in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis. Antimicrobial Agents Chemother, 2004, 48(11): 4447-4449.[16]Sekiguchi J, Miyoshi-Akiyama T, Augustynowicz-KopecE, et al. Detection of multidrug resistance in Mycobacterium tuberculosis. J Clin Microbiol, 2007, 45(1): 179-192.[17]Perdigao J, Macedo R, Ribeiro A, et al. Genetic characterisation of the ethambutol resistance-determining region in Mycobacterium tuberculosis: prevalence and significance of embB306 mutations. Int J Antimicrob Agents, 2009,33(4):334-338.[18]Campbell PJ, Morlock GP, Sikes RD, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother,2011,55(5):2032-2041.[19]张楠, 胡继红, 万康林. 乙胺丁醇耐药表型与耐药基因embB突变的关系. 中国卫生检验杂志,2010,20(3):490-492.[20]Brossier F, Veziris N, Aubry A, et al. Detection by Geno Type MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol,2010,48(5): 1683-1689.[21]Hazbón MH, Bobadilla del Valle M, Guerrero MI, et al. Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother, 2005,49(9):3794-3802.[22]Zhang SL, Qi H, Qiu DL, et al. Genotypic analysis of multidrug-resistant Mycobacterium tuberculosis isolates recovered from central China. Biochem Genet,2007, 45(3-4):281-290.[23]Guo JH, Xiang WL, Zhao QR, et al. Molecular characterization of drug-resistant Mycobacterium tuberculosis isolates from Sichuan Province in China. Jpn J Infect Dis, 2008,61(4):264-268.[24]Plinke C, Cox HS, Kalon S, et al. Tuberculosis ethambutol resistance: concordance between phenotypic and genotypic test results. Tuberculosis (Edinb), 2009, 89(6):448-452.[25]Hu Y, Hoffner S, Jiang W, et al. Genetic characterisation of drug-resistant Mycobacterium tuberculosis in rural China: a population-based study. Int J Tuberc Lung Dis, 2010,14(2):210-216.[26]Shi D, Li L, Zhao Y, et al. Characteristics of embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates in Henan, China. J Antimicrob Chemother,2011,66(10):2240-2247.[27]Huang WL, Chi TL, Wu MH, et al. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol,2011,49(7):2502-2508.[28]林辉.重庆市结核病耐药的流行病学调查及耐药相关基因分子特征研究.重庆:第三军医大学,2008.[29]Hillemann D,Rüsch-Gerdes S,Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol,2009, 47(6): 1767-1772.[30]Miotto P, Cabibbe AM, Mantegani P, et al. GenoType MTBDRsl performance on clinical samples with diverse genetic background. Eur Respir J, 2012,40(3): 690-698.[31]郭琪,李觉,胡忠义,等. 焦磷酸测序技术检测结核分枝杆菌异烟肼耐药性的Meta分析.中华检验医学杂志,2013,36(4):329-332.[32]Plinke C, Rüsch-Gerdes S, Niemann S. Significance of mutations in embB codon 306 for prediction of ethambutol resis-tance in clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother, 2006,50(5):1900-1902.[33]Parsons LM, Salfinger M, Clobridge A, et al. Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol.Antimicrob Agents Chemother,2005,49(6):2218-2225.[34]Xu HB, Jiang RH, Sha W, et al. PCR-single-strand conformational polymorphism method for rapid detection of rifampin-resistant Mycobacterium tuberculosis: Systematic review and meta-analysis. J Clin Microbiol, 2010, 48(10):3635-3640. |